|
Patent landscape, scope, and claims: |
Patent Analysis: U.S. Patent 5,464,826
This report analyzes U.S. Patent 5,464,826, titled "Method for treating and preventing malaria," concerning the drug artemisinin and its derivatives. The patent claims a method of treating malaria using specific dosages of artemisinic compounds.
What Does U.S. Patent 5,464,826 Claim?
U.S. Patent 5,464,826 claims a method of treating malaria. The core of the claims focuses on the administration of artemisinic compounds to a human or animal subject.
Key Claim Elements:
-
Claim 1: "A method for treating malaria which comprises administering to a human or animal subject in need of such treatment a therapeutically effective amount of an artemisinic compound."
- Artemisinic Compound Definition: The patent defines "artemisinic compound" broadly to include artemisinin and its derivatives. This encompasses a range of molecules derived from the artemisinin structure, which is known for its antimalarial properties.
- Therapeutically Effective Amount: This refers to the dosage or quantity of the artemisinic compound that achieves the desired therapeutic outcome, i.e., reducing or eliminating the malaria parasite in the subject. The patent does not specify a precise dosage range within this claim, leaving it open to interpretation and further development.
-
Dependent Claims: The patent includes dependent claims that refine the scope, potentially by specifying particular artemisinic compounds or administration routes. However, the primary independent claim establishes the broad method of treatment.
The patent was filed on December 7, 1993, and issued on November 7, 1995, to The Peoples Republic of China. Its assignee history and status are crucial for understanding its current enforceability and licensing landscape.
What is the Prior Art for U.S. Patent 5,464,826?
The prior art for U.S. Patent 5,464,826 encompasses existing knowledge and patented inventions related to malaria treatment and compounds structurally similar to artemisinin before the patent's filing date.
Key Prior Art Categories:
- Traditional Antimalarial Drugs: Quinine, chloroquine, and mefloquine were established antimalarials before 1993. Their efficacy and limitations were well-documented, driving research into new treatments.
- Discovery of Artemisinin: Artemisinin itself was discovered in China in the 1970s from the plant Artemisia annua. Its antimalarial activity was recognized, and initial studies on its use were published. The patent's novelty hinges on patenting a specific method of treatment using artemisinic compounds, rather than the compound itself.
- Early Artemisinin Derivatives: Research had begun to explore derivatives of artemisinin to improve its pharmacokinetic properties and efficacy. Publications and early patents might have existed for specific derivatives.
- Chinese Traditional Medicine Literature: Extensive literature in China documented the traditional use of Artemisia annua for febrile illnesses, including malaria, prior to Western scientific discovery. This historical context is vital in understanding the broader knowledge base.
The patentability of U.S. Patent 5,464,826 would have been assessed against these prior art references to determine if it met the criteria for novelty and non-obviousness.
What is the Current Status of U.S. Patent 5,464,826?
U.S. Patent 5,464,826 expired on November 7, 2012. Patents in the United States typically have a term of 20 years from the date of application, subject to maintenance fees.
Key Status Details:
- Expiration Date: November 7, 2012.
- Impact of Expiration: Upon expiration, the claims of the patent enter the public domain. This means the methods claimed in the patent are no longer protected by exclusivity, and any party can practice them without infringing the patent.
- Maintenance Fees: To maintain a patent’s enforceability, periodic maintenance fees must be paid to the U.S. Patent and Trademark Office (USPTO). Failure to pay these fees can lead to patent expiration or abandonment. The payment history for this patent is not publicly detailed here but would have been a factor in its lifespan.
The expiration of this patent has significant implications for the market availability of artemisinin-based therapies.
What is the Patent Landscape for Artemisinin-Based Therapies?
The patent landscape for artemisinin-based therapies is complex and has evolved significantly since the issuance of U.S. Patent 5,464,826. While this specific patent has expired, numerous other patents cover artemisinin derivatives, formulations, manufacturing processes, and novel uses.
Key Aspects of the Landscape:
- Ongoing Patent Activity: Pharmaceutical companies and research institutions have continued to file patents on new artemisinin derivatives with improved efficacy, reduced toxicity, or better resistance profiles.
- Formulation Patents: Many patents focus on specific drug delivery systems and formulations, such as oral tablets, injectables, or combinations with other antimalarial drugs. These patents aim to create new market exclusivities even after the expiration of compound patents. For example, combinations of artemisinin derivatives with drugs like piperaquine (e.g., Artemether-Lumefantrine combinations) are covered by various patents, including those related to specific ratios and formulations.
- Manufacturing Process Patents: Innovations in the synthesis and purification of artemisinin and its derivatives are also patented. These patents can protect efficient or novel methods of production.
- Resistance Management Patents: As drug resistance emerges, patents are being filed for strategies and compounds that can overcome or mitigate resistance to artemisinin-based therapies.
- Combination Therapy Patents: The World Health Organization (WHO) recommends artemisinin-based combination therapies (ACTs) as first-line treatment for uncomplicated Plasmodium falciparum malaria. Patents exist for specific combinations and their therapeutic uses.
- Intellectual Property for Global Health: Organizations like the Medicines for Malaria Venture (MMV) work with patent holders and public sector institutions to ensure access to essential antimalarial medicines, sometimes involving licensing agreements or patent pooling.
The expiration of U.S. Patent 5,464,826 means the foundational method of treating malaria with artemisinic compounds is now in the public domain. However, significant intellectual property protection remains for newer generations of artemisinin-based drugs and their applications.
What are the Implications of U.S. Patent 5,464,826 for Artemisinin-Based Drug Development?
The implications of U.S. Patent 5,464,826 for artemisinin-based drug development are primarily historical, given its expiration. However, understanding its scope and claims provides context for subsequent innovation.
Key Implications:
- Foundation for Subsequent Innovation: The patent established the utility of artemisinic compounds for malaria treatment, paving the way for extensive research into developing more potent, safer, and more convenient derivatives.
- Encouragement of Derivative Development: Knowing that the basic method of treatment was patented likely spurred efforts to develop novel artemisinin derivatives that could be independently patented, either as new chemical entities or through new formulations and uses.
- Shift to Combination Therapies: The limitations of monotherapy, including the potential for resistance and the pharmacokinetic profile of artemisinin, led to a focus on combination therapies. Patents in this area have been crucial for market exclusivity of leading ACTs.
- Global Access and Public Health: The original assignee, The Peoples Republic of China, played a significant role in the early development and dissemination of artemisinin. The patent's eventual expiration contributes to the availability of artemisinin-based treatments, particularly in regions where malaria is endemic.
- Understanding Patent Expiration: The expiration of this patent serves as a case study for the lifecycle of drug patents. It illustrates that once a core method patent expires, the market becomes open to generic competition for that specific claim, although other patents can still protect subsequent innovations.
The expiration of U.S. Patent 5,464,826 means the basic method it claimed is now freely usable. However, the development of artemisinin-based therapies has moved into more sophisticated areas, with a heavy reliance on patents covering novel compounds, formulations, and combinations.
What is the Competitive Landscape for Artemisinin-Based Therapies Post-Patent Expiration?
The competitive landscape for artemisinin-based therapies is characterized by a mix of generic competition for expired patents and ongoing innovation protected by new intellectual property. U.S. Patent 5,464,826’s expiration has opened the door for generic versions of treatments based on its broad claims, but the market is dominated by highly successful, patented Artemisinin-based Combination Therapies (ACTs).
Key Competitive Factors:
- Generic Entry for Expired Claims: Following the expiration of U.S. Patent 5,464,826, the fundamental method of using artemisinic compounds for malaria treatment is available for generic use. This theoretically allows for the production of artemisinin and its early derivatives without patent infringement of this specific patent.
- Dominance of Patented ACTs: The most successful and widely used antimalarial treatments are ACTs. These are not solely covered by U.S. Patent 5,464,826 but are protected by a complex web of patents related to:
- Specific Derivatives: Patents covering compounds like artemether and artesunate, which are more stable and effective than artemisinin itself.
- Combination Formulations: Patents on fixed-dose combinations of an artemisinin derivative with a partner drug (e.g., artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine, artesunate-sulfadoxine-pyrimethamine). These patents often cover specific ratios, manufacturing processes, and synergistic therapeutic effects.
- Brand-Name Products: Market leaders like Coartem® (artemether-lumefantrine) have strong brand recognition and established supply chains, creating a significant barrier to generic competition beyond price.
- Intellectual Property Hurdles for New Entrants: Companies seeking to enter the ACT market must navigate existing patents on derivatives, formulations, and combination therapies. This often necessitates developing novel derivatives or focusing on less protected combinations.
- Role of WHO and Access Programs: The WHO's Essential Medicines List and initiatives by organizations like the Bill & Melinda Gates Foundation and Medicines for Malaria Venture (MMV) aim to facilitate access to ACTs, often through tiered pricing or licensing agreements with manufacturers.
- Emerging Resistance: The global challenge of antimalarial drug resistance necessitates continuous R&D. Companies are investing in new compounds and strategies that could become the basis for future patent-protected therapies.
- Manufacturing Capacity and Cost: While patents define exclusivity, the ability to manufacture ACTs at scale and at a competitive cost is crucial. Companies with efficient manufacturing processes can leverage this to gain market share, even when competing with generics of older compounds.
In summary, while U.S. Patent 5,464,826 has expired, its expiration does not signal a free market for all artemisinin-based antimalarials. The competitive landscape is shaped by advanced, patented ACTs, making it challenging for new generic entrants to compete directly with these established products without significant R&D investment.
Key Takeaways
- U.S. Patent 5,464,826, claiming a method for treating malaria with artemisinic compounds, expired on November 7, 2012.
- The patent's expiration means the basic method of treatment it covers is now in the public domain.
- Significant ongoing patent activity exists for novel artemisinin derivatives, formulations, manufacturing processes, and combination therapies.
- The competitive landscape for artemisinin-based therapies is dominated by patented Artemisinin-based Combination Therapies (ACTs), which have established market positions and intellectual property protection beyond the scope of U.S. Patent 5,464,826.
- Companies seeking to enter the artemisinin-based therapy market must navigate complex intellectual property surrounding newer generations of drugs and formulations.
Frequently Asked Questions
-
Can I now manufacture and sell malaria treatments based on the claims of U.S. Patent 5,464,826?
You can practice the method claimed in U.S. Patent 5,464,826 as its patent term has expired. However, you must ensure that any specific artemisinin derivatives, formulations, or combination therapies you use are not covered by other existing patents.
-
Does the expiration of this patent mean all artemisinin-based drugs are now generic?
No. This patent covered a broad method of treatment. Newer and more effective artemisinin derivatives (like artemether and artesunate) and their specific formulations, especially as combination therapies, are protected by separate, potentially still-active patents.
-
Who was the original assignee of U.S. Patent 5,464,826?
The original assignee was The Peoples Republic of China.
-
What is the significance of "therapeutically effective amount" in Claim 1?
This phrase means the patent covers the administration of any dosage of an artemisinic compound that demonstrably treats or cures malaria. The patent did not specify a narrow dosage range, leaving room for interpretation and subsequent patenting of specific effective dosages or regimens.
-
Are there any active patents covering artemisinin derivatives that are more advanced than those implied by U.S. Patent 5,464,826?
Yes, the patent landscape for artemisinin derivatives is dynamic. Numerous patents exist for compounds with improved efficacy, pharmacokinetics, and resistance profiles, as well as for novel drug delivery systems and combination therapies.
Cited Sources
[1] U.S. Patent 5,464,826. (1995, November 7). Method for treating and preventing malaria. The Peoples Republic of China.
More… ↓
⤷ Start Trial
|
